Considering chemotherapy is presumed to have a relatively non-selective cytotoxic effect on all rapidly dividing cells, whereas osimertinib acts against activating and resistance EGFR mutations7, the association of T790M subclonality with shorter PFS on both treatments could be influenced by other, non-T790M alterations co-occurring in these tumours. This evidence concerns the gene EGFR and neoplasm.